NIILO MAKI -SAATIO

Their core work

The Niilo Mäki Institute (NMI) is a Finnish research and service center dedicated to understanding and addressing learning disabilities and neurodevelopmental disorders in children. Their scientific work combines multi-modal brain imaging — EEG, MEG, MRI, and fMRI — with behavioral research to map how atypical brain development leads to conditions such as dyslexia, autism, and related disorders. In H2020 projects, they contribute specialist clinical and neuroimaging expertise, helping to identify early biomarkers that could predict risk and guide intervention. They bridge laboratory neuroscience and real-world clinical application, which is rare among institutions of their size.

What they specialise in

How they've shifted over time

In their first H2020 project (ChildBrain, 2015–2019), NMI's role was that of a partner in a broad consortium advancing brain research across children's neurocognitive disorders — no specific sub-topics were tagged in the data, suggesting a supporting or generalist contribution. By the time Neo-PRISM-C began (2018–2023), their involvement is far more technically defined: multi-modal imaging, biomarker identification, computational modelling, and the RDoC framework signal a shift toward precision neuroscience and predictive approaches. The trend is clearly toward systems-level, data-rich methods for early detection and intervention, rather than descriptive disorder research.

NMI is moving toward integrating multi-modal neuroimaging with computational models to predict neurodevelopmental risk early — a direction with strong relevance for clinical diagnostics, digital health tools, and personalised intervention design.

How they like to work

NMI has never coordinated an H2020 project, always appearing as a partner or third party — they are a specialist contributor, not a project driver. Both of their projects sit under the MSCA-ITN scheme, which means they work within large training networks with many institutions, explaining their 27 unique partners across just 2 projects. They are the kind of organisation you recruit for their specific clinical-scientific expertise, not to lead administration or strategy.

Despite only two H2020 projects, NMI has collaborated with 27 partners across 12 countries — a product of the large MSCA-ITN training network structure, which typically involves 10–20 institutions per consortium. Their network is genuinely pan-European, with no visible geographic concentration.

What sets them apart

The Niilo Mäki Institute occupies a rare niche: a non-university research center in the Nordic region with simultaneous depth in clinical learning disability services and neuroscience research, particularly neuroimaging in children. Most imaging-capable institutions are large universities; most specialist learning disability centers lack imaging infrastructure — NMI bridges both worlds. For consortia targeting child populations, early intervention, or neurodevelopmental biomarkers, they offer clinical access and scientific credibility that few organizations of their scale can match.

Highlights from their portfolio

• Neo-PRISM-C
  The most technically ambitious project in their H2020 portfolio, bringing together multi-modal brain imaging, biomarker discovery, and systems modelling under a single MSCA training network — and the only project for which they received direct EC funding (EUR 280,806).
• ChildBrain
  Their entry into H2020 collaboration, establishing their position within an international consortium tackling children's neurodevelopmental disorders before the more specialised Neo-PRISM-C work began.